The biotech industry has long operated on a simple premise: FDA-regulated, evidence-based science determines how medicines reach patients, not litigation. That premise was already tested in an earlier Texas case challenging mifepristone’s Food and Drug Administration approval — an unprecedented effort to unwind decades of scientific review through the courts. It is now, once again, under strain.
On Friday, the 5th Circuit Court of Appeals reinstated an in-person dispensing requirement for mifepristone, a medication that has been used safely by millions for more than two decades. The drug manufacturer, Danco, appealed to the Supreme Court within hours and on Monday morning, SCOTUS granted one-week stay halting the order. In other words, mifepristone is available again through the mail and at pharmacies — but it’s unclear for how long that will be true. And it signals that even well-established, FDA-approved medicines are vulnerable to judicial override of FDA regulatory decisions.
Louisiana v. FDA is one of several cases seeking to eliminate access to mifepristone altogether. Importantly, the FDA had also asked for a stay of the ruling, and since July 2025 has been conducting its own review of the mifepristone Risk Evaluation and Mitigation Strategies (REMS) under established regulatory processes. Now, in a chaotic back-and-forth between the federal courts, we are waiting for the Supreme Court to weigh in.
Even if the ruling has temporarily restored access, the case should concern every leader in biotech and pharmaceuticals, regardless of where they stand on reproductive health.
First, if upheld, this ruling would disrupt access to a safe, well-established medication for millions of patients. Mifepristone’s safety and efficacy are not in question. It is supported by decades of clinical data and real-world use. Yet the 5th Circuit wants to impose new barriers untethered from that evidence. For patients (especially those in rural and underserved communities) this means more travel, more time away from work and family, and more difficulty completing what has long been a straightforward course of care.
It also took effect immediately, which, for a time-sensitive medical condition, is egregious. With the whiplash of the past few days, providers and patients are understandably confused. Imagine, for example, a patient in the midst of a novel cell therapy, where every hour counts, and their method of obtaining treatment was suddenly upended at the precise moment it was needed most.
Second, it would put added strain on the health care system. Requiring in-person dispensing for a medication long prescribed via telehealth would force clinics to absorb new demand, providers to reallocate limited time, and patients to navigate avoidable delays. It also moves health care away from telehealth, which is now a basic part of how care is delivered, and back toward more fragmented, in-person-only systems. We should be embracing technology to improve health care outcomes and access, not going backward.
Third, this case risks setting a destabilizing precedent for the entire biotech and pharmaceutical industry. The ruling cut around the established process for how drug access and labeling decisions are made. Typically, any change to how a medication is prescribed or distributed comes through a defined pathway: The sponsor submits updated data, and the FDA reviews and either approves or rejects it. Courts do not play a role in that process. By stepping in here, the 5th Circuit introduced confusion about how these decisions are supposed to work.
That uncertainty has consequences. If drug developers and investors cannot rely on a predictable, science-based FDA process to govern how products reach patients, they will be far more hesitant to move forward, especially in areas that could become politically contested. You can imagine the slippery slope: If one state decides it doesn’t like a medication (for example, vaccines, contraception, or other widely used treatments), it could try to use the courts to impose nationwide restrictions or barriers. Over time, this kind of instability slows innovation and risks driving away investment.
The United States has long been a global leader in biotechnology precisely because it has upheld a clear division of roles: Scientists generate evidence, regulators evaluate safety and efficacy, and companies bring innovations to market.
This ruling is bad for health care access, and it’s also bad for innovation. When it makes its final ruling, the Supreme Court should clarify the boundaries of judicial versus regulatory authority. The FDA should be allowed to complete its ongoing review of the mifepristone REMS strictly based on peer-reviewed, well substantiated science.
Biotechnology leaders from across the ecosystem — drug developers, investors, and all who support and benefit from the industry — should be united and vocal about this. If uncertainty replaces evidence as the guiding principle of drug availability, we risk slowing discovery, deterring investment, and ultimately failing the patients who depend on us.
Grace E. Colón, Ph.D., is the president and CEO of OmniPulse Biosciences and serves on the boards of several public and private biotechnology companies.
